|
|
Mometasone furoate Shows Substantial Improvement in Lung Function in Persistent Asthma
Apr 1, 2005 - 9:14:00 AM, Reviewed by: Dr.
|
|
"Mometasone furoate is a highly effective first-line therapy that offers health care professionals and their patients a once daily therapy to help prevent persistent asthma symptoms."
|
By Akanksha, Pharmacology Correspondent,
Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the use of ASMANEX� TWISTHALER� 220 mcg (mometasone furoate inhalation powder) for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older.
Mometasone furoate is also the only inhaled asthma controller therapy approved for once daily initiation and management of asthma in patients previously treated with bronchodilators alone or inhaled corticosteroids. Clinical studies with Mometasone furoate have shown substantial improvement in lung function, decreased use of rescue medication, decreased incidence of nighttime awakenings and significant improvements in daytime symptoms such as coughing and wheezing.
"Mometasone furoate is a highly effective first-line therapy that offers health care professionals and their patients a once daily therapy to help prevent persistent asthma symptoms," said Harold Nelson MD, Professor of Medicine, Department of Medicine, National Jewish Medical and Research Center, University of Colorado Health Science Center in Denver, Colo.
In a clinical trial, Mometasone furoate showed substantial improvement in lung function and decreased albuterol (rescue medication) use compared with placebo, as evidenced by a 12-week, multicenter, randomized, double-blind, placebo-controlled study of 400 patients with persistent asthma previously dependent on inhaled corticosteroid therapy.
At endpoint, patients who received Mometasone furoate had a significant improvement in nighttime awakenings and daytime symptoms -- providing night and day relief.
The NAEPP (National Asthma Education and Prevention Program) asthma treatment guidelines recommend single-ingredient, low-dose inhaled corticosteroid as the foundation of therapy for mild persistent asthma management.
Asthma is a chronic inflammatory lung disease that affects a growing number of Americans each year. The number of cases has grown steadily in the past 20 years, making it one of the leading public health problems in the U.S.
As many as 20 million people suffer from asthma. On an annual basis, this leads to at least two million emergency room visits and more than 5,000 deaths. Additionally, this accounts for an annual direct cost of treatment of $9.4 billion and approximately 14.5 million missed work days. Asthma symptoms such as coughing, wheezing, and shortness of breath occur during the day and night, impacting multiple aspects of patients' lives. Daytime symptoms can affect activities ranging from exercise to going to school or work. Nighttime symptoms interfere with patients' ability to sleep.
Mometasone furoate was discovered and developed by Schering-Plough Research Institute and is currently approved for asthma treatment in more than 40 countries. Mometasone furoate, the active ingredient in Mometasone furoate, was first introduced in the U.S. in 1987 as the dermatologic ointment, ELOCON (mometasone furoate ointment) and in 1997 as the nasal spray,NASONEX (mometasone furoate monohydrate).
In clinical trials with Mometasone furoate, adverse events were generally mild to moderate in severity. The following incidence of common adverse experiences is based on double-blind data from ten placebo-controlled clinical trials involving a total of 2,809 patients previously maintained on inhaled steroids and/or bronchodilators (1,140 males, 1,669 females, age 12-83 years), who were treated for up to 12 weeks with the Mometasone furoate product, an active comparator, or placebo.
Adverse events were generally mild to moderate in severity and included headache, allergic rhinitis, pharyngitis, upper respiratory infection, sinusitis, oral candidiasis, dysmenorrhea, musculoskeletal pain, back pain, dyspepsia, myalgia, abdominal pain, and nausea.
Mometasone furoate offers an effective inhaled corticosteroid to control asthma symptoms in an easy to use device that was awarded the DuPont Award for innovation in packaging. The Mometasone furoate Inhaler employs an inhalation- driven device that does not use a propellant, thus eliminating the need for hand-breath coordination, and it provides patients with a numeric dose counter that provides a visual indication of the remaining doses.
Recommended starting dose of Mometasone furoate is one inhalation daily in the evening for patients previously treated with bronchodilators alone or inhaled corticosteroids. For patients previously maintained on oral corticosteroids, the recommended starting dose of Mometasone furoate is two inhalations twice daily.
Mometasone furoate is expected to be available in the U.S. in the autumn of 2005. 
- United States Food and Drug Administration (FDA)
Schering-Plough
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. The company is based in Kenilworth, N.J.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
